Trial Profile
A Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs ACB2003.4 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 09 Nov 2011 Results were reported at the annual meeting of the American College of Rheumatology, according to a Lexicon Pharmaceuticals media release.
- 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.